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Human cytomegalovirus (HCMV) is a widespread pathogen in the human population, affecting many immunologically imma-
ture and immunocompromised patients, and can result in severe complications, such as interstitial pneumonia andmental re-
tardation. Current chemotherapies for the treatment of HCMV infections include ganciclovir (GCV), foscarnet, and cidofovir.
However, the high incidences of adverse effects (neutropenia and nephrotoxicity) limit the use of these drugs. Cyclopropavir
(CPV), a guanosine nucleoside analog, is 10-fold more active against HCMV than GCV (50% effective concentrations [EC50s]!
0.46 and 4.1"M, respectively). We hypothesize that the mechanism of action of CPV is similar to that of GCV: phosphorylation
to a monophosphate by viral pUL97 protein kinase with further phosphorylation to a triphosphate by endogenous kinases, re-
sulting in inhibition of viral DNA synthesis. To test this hypothesis, we isolated a CPV-resistant virus, sequenced its genome, and
discovered that bp 498 ofUL97was deleted. This mutation caused a frameshift inUL97 resulting in a truncated protein that
lacks a kinase domain. To determine if this base pair deletion was responsible for drug resistance, the mutation was engineered
into the wild-type viral genome, which was then exposed to increasing concentrations of CPV. The results demonstrate that the
engineered virus was approximately 72-fold more resistant to CPV (EC50! 25.8# 3.1"M) than the wild-type virus (EC50!
0.36# 0.11"M).We conclude, therefore, that this mutation is sufficient for drug resistance and that pUL97 is involved in the
mechanism of action of CPV.
Human cytomegalovirus (HCMV), a betaherpesvirus, is awidespread pathogen affecting amajority of the world’s pop-
ulation (1). Individuals at risk for symptomatic HCMV disease—
which includes interstitial pneumonia, encephalitis, and retini-
tis—are those with deficiencies in T-cell immunity. In addition,
withmore than 4,000 cases reported each year, HCMV is themost
common congenital infection in the United States and can result
in severe mental retardation, hearing loss, and/or vision loss (2).
The drugs currently approved by the FDA for the prophylaxis or
treatment of systemic HCMV infections are ganciclovir (GCV)
(Fig. 1) and its oral prodrug valganciclovir, foscarnet, and cidofo-
vir (3–5). GCV is the most common therapy option for the
treatment of HCMV infections among patients with impaired im-
munity, particularly those with advanced HIV/AIDS, those un-
dergoing cancer chemotherapy, and recipients of solid-organ or
bone marrow transplants (6–8). GCV, an acyclic analog of the
nucleoside guanosine, is converted intracellularly to amonophos-
phate by a viral protein kinase encoded by the HCMV gene UL97
(9, 10). Upon further phosphorylation by cellular enzymes (11,
12), GCV triphosphate competes with endogenous dGTP for in-
corporation into progeny viral genomes, resulting in pUL54 (viral
DNA polymerase) inhibition (13, 14). Once incorporated, GCV
also acts as a chain terminator, further inhibiting viral DNA syn-
thesis (15, 16). However, long-term therapy is typically required
due to recurrence of infection and reactivation of latent HCMV
upon cessation of therapy. Drug resistance and adverse effects,
such as neutropenia (affecting as many as 30% of patients) and
nephrotoxicity (affecting as many as 50% of patients), are preva-
lent and limit the use of GCV, foscarnet, and cidofovir (3, 17–19).
With the increased use of immunosuppression for cancer chemo-
therapy and organ transplantation, there is an increasing need for
more-effective and less-toxic drugs to treat HCMV.
Cyclopropavir(CPV)(Fig.1),amethylenecyclopropaneguano-
sine nucleoside analog, is currently being explored as a viable che-
motherapy option for HCMV due to its high potency and low
incidence of adverse effects in vivo (20, 21). Previous studies have
demonstrated that CPV is approximately 10-fold more active in
vitro (50% effective concentration [EC50]! 0.46 "M) than GCV
(EC50! 4.1 "M), with no observed increase in cytotoxicity (22).
Furthermore, CPV elicits a 2- to 5-log reduction in murine cyto-
megalovirus titers in vivo, resulting in reduced mortality in SCID
mice (21). Although the mechanism of action of CPV has been
hypothesized in previous studies, the exact mechanism by which
CPV elicits an antiviral effect has not been determined (23). We
have established that both CPV and GCV are phosphorylated to
monophosphates by viral pUL97 protein kinase (24). Additional
phosphorylation to a triphosphate by endogenous kinases is also
similar for CPV and GCV (25). However, viral DNA polymerase
inhibition and incorporation into HCMV are known for GCV
(13–16) but have not been established for CPV. Furthermore, the
necessity of phosphorylation by pUL97 for antiviral activity is un-
known. Thus, the goal of this study is to determine whether the
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viral protein kinase pUL97 is involved in themechanism of action
of CPV.
MATERIALS AND METHODS
Chemicals. CPV was synthesized in the laboratory of J. Zemlicka as de-
scribed previously (22). GCV was kindly provided by Hoffmann-La
Roche (Palo Alto, CA).
Cell culture procedures. Human foreskin fibroblasts (HFF) were
grown in minimal essential medium with Earle’s salts and 10% fetal bo-
vine serum. They were grown at 37°C under a humidified atmosphere of 3
to 5% CO2 and 97 to 95% air and were regularly passaged at 1:2 dilutions
using conventional procedures with 0.05% trypsin and 0.02% EDTA in
HEPES-buffered saline (26).
Viral strain. The HCMV strain Towne was kindly provided by M. F.
Stinski, University of Iowa. A bacterial artificial chromosome (BAC) clone
of strain AD169 (AD169rv) was generously provided by U. H. Koszi-
nowski, Ludwig-Maximilians University (Munich, Germany) (27).
HCMVplaque reduction assay.HFFwere seeded at 85,000 perwell in
a 24-well cluster dish and were infected 3 days later with HCMV at 100
PFU per well. Two hours postinfection, media containing serial dilutions
of drug, fetal bovine serum (final concentration, 3%), and 0.5% methyl-
cellulose were added. After incubation at 37°C for 9 to 11 days, cell mono-
layers were stained with crystal violet, and plaques were enumerated by
lightmicroscopy. The number of plaques observed in the presence of each
drug concentration was compared to the number observed in the absence
of the drug in order to determine the drug effect. The percentage of inhi-
bition of plaque numbers was plotted against the log10 drug concentra-
tion. Fifty percent effective concentrations (EC50s) were interpolated
from the linear portions of the regression lines. All drug dilutions were
tested at least in duplicate.
Selection of CPV-resistant virus.HFFwere infected with HCMV at a
multiplicity of infection (MOI) of 0.01 and were grown in a 25-cm2 tissue
culture flask in the presence of 0.5 "M CPV for 2 weeks. Supernatant
progeny virus was then passaged in the presence of first 1.0 "M and then
2.0"Mconcentrations of CPV; the duration of each passage was 2 weeks.
The resulting virus was further passaged in 2.0"MCPV for 3months and
was then frozen in liquid nitrogen, and the titer was determined. The
resulting virus stock was purified using the Klein limiting-dilution
method (28) and was termed 2696r.
DNA sequencing. Primers for PCR amplification and sequencing
were determined on the basis of the published sequence of the Towne
strain of HCMV. After PCR amplification, products were run on a 0.8%
agarose gel, extracted, and purified using a QIAquick gel extraction kit
(Qiagen, Valencia, CA). Sequencing PCRwas carried out with the BigDye
Terminator cycle-sequencing ready-reaction kit (Applied Biosystems,
Foster City, CA), and sequencing reaction products were separated and
detected with an ABI Prism 310 genetic analyzer. Sequences were aligned
and edited using Sequencher software (Gene Codes, Ann Arbor, MI).
Western blot analysis. HFF were infected with wild-type HCMV or
2696r at an MOI of approximately 1.0 PFU/ml and were grown in a 75-
cm2 tissue culture flask. After 4 days, cells were harvested and were lysed
using lysis buffer (2%NP-40, 0.1MTris [pH8.8], 0.1%SDS, 0.3MNaCl),
and protein levels were determined using the DC protein assay (Bio-Rad
Corp., Hercules, CA). Fifty micrograms of protein per sample was elec-
trophoresed under reducing conditions and was blotted electrophoreti-
cally onto nitrocellulose paper (Bio-RadCorp.,Hercules, CA). pUL97was
detected using a previously characterized polyclonal antibody developed
against full-length pUL97 (a generous gift of Don Coen, Harvard Univer-
sity, Boston, MA) (29) and the SuperSignal West Pico chemiluminescent
substrate imaging system (Thermo Scientific, Rockford, IL). A monoclo-
nal antibody against human actin was used as a loading control.
Marker transfer studies. “En passant” mutagenesis of BACs was per-
formed as described elsewhere (30–32) to remove bp 498 of the UL97
open reading frame from a BAC clone of HCMV strain AD169, AD169rv
(a generous gift of Ulrich Koszinowski) (27). All manipulations were per-
formed in Escherichia coli strain GS1783 (a generous gift of Greg Smith,
Northwestern University, Chicago, IL). Briefly, an excisable kanamycin
resistance marker (I-SceI-aphAI) was amplified from a plasmid template
by using oligonucleotide primers d_bp498_F (5=-AAA CTT CGG CCA
TGT GGT CGT TCG AGT ACG ATC GCG ACG GGA CGT GAC CAG
CG T ACG CCG TAG GGA TAA CAG GGT AAT CGA TTT-3=) and
d_bp498_Rv (5=-TGC CGC CGG TGA AGA GAG CGC GGC GTA CGC
TGG TCA CGT CCC GTC GCG ATC GT A CTC GAA GCC AGT GTT
ACA ACC AAT TAA CC-3=), which had been custom synthesized, and
was purified via polyacrylamide gel electrophoresis (PAGE) by Integrated
DNA Technologies, Inc. (Coralville, IA). The resulting PCR product was
gel purified using a NucleoSpin gel and PCR cleanup kit (Macherey-Na-
gel, Inc., Bethlehem, PA) andwas then electroporated into E. coli contain-
ing the AD169rv BAC. Integrated colonies were resolved to remove the
kanamycin resistance marker. The resulting recombinant BAC, AD169rv
d498, was confirmed by restriction enzyme digestion analysis and byDNA
sequencing of the modified region (Genewiz, Inc., South Plainfield, NJ).
Virus reconstitution. Infectious virus was reconstituted from BAC
DNA as described previously (32), by cotransfection of #0.7 $ 105 hu-
man foreskin fibroblasts in a 24-well cluster plate (Corning, Inc.) with a
total of 1 "g DNA containing 750 ng BAC DNA, 200 ng of the pp71
expression plasmid pSG5-pp71 (33) (a gift of Robert Kalejta, University of
Wisconsin, Madison, WI), and 50 ng of the Cre recombinase expression
plasmid pCAGGS-nlsCre (34) (a gift of Michael I. Kotlikoff, Cornell Uni-
versity, Ithaca, NY), by using 7 "l of Superfect transfection reagent
(Qiagen, Inc., Valencia, CA) according to themanufacturer’s recommen-
dations.
HCMV growth assay.HFF were seeded and grown to confluence in a
25-cm2 tissue culture flask at 37°C. Cells were then infected with virus at
anMOI of 0.02. Two hours postinfection, mediumwas added to the flask,
and samples were collected every 24 h over the course of 10 days (collected
samples were stored at%80°C until titers could be determined). The titer
of virus for each sample was determined by first plating a 96-well plate
with HFF grown to confluence. Serial dilutions (1:3) of samples (total
volume, 200"l) were then plated, and the virus was allowed to grow for 7
to 9 days at 37°C. Finally, cell monolayers were stained with crystal violet
and plaques were enumerated by light microscopy. The virus titer was
calculated as 5$ 3n$ the number of plaques, where n is the serial dilution
in which the plaques were enumerated.
RESULTS
Initial isolation and characterization of 2696r (CPV-resistant
HCMV).We hypothesize that the mechanism of action of CPV is
a multiphase process: initial phosphorylation by viral pUL97 to a
monophosphate, followed by phosphorylation by endogenous ki-
nases to a triphosphate, resulting in the inhibition of viral DNA
synthesis. Although we have demonstrated previously that CPV is
phosphorylated by pUL97 to amonophosphate (the initial step of
our hypothesis) (24), it has not been determined whether this
enzymatic conversion is necessary for CPV to elicit an antiviral
effect. Therefore, to test the first step of our hypothesis, HFF in-
FIG 1 Structures of ganciclovir (GCV) and cyclopropavir (CPV).
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fected with a CPV-resistantHCMV strain (2696r) were exposed to
increasing concentrations of the drug in order to confirm resis-
tance (Fig. 2; Table 1). As expected, 2696r was approximately 25-
fold more resistant to CPV (EC50 ! 22.5 & 3.5 "M) than the
wild-type (Towne strain) virus (EC50! 0.91& 0.15 "M). In ad-
dition, HFF infected with 2696r were exposed to increasing con-
centrations of GCV in order to determine if the virus is also resis-
tant to this drug. As shown in Fig. 2, 2696r is approximately
28-fold more resistant to GCV (EC50! 41.3& 2.8 "M) than the
wild-type virus (EC50 ! 1.5 & 0.16 "M). These results demon-
strate that 2696r, which is resistant to CPV, exhibits cross-resis-
tance with GCV.
DNA sequencing of 2696r. Since 2696r was resistant to GCV,
and GCV resistance has been mapped to mutations in UL54 and
UL97 (17, 18), the open reading frames ofUL54 andUL97 in 2696r
were sequenced. The results demonstrated that the open reading
frameofUL54 in 2696r containednomutations, whereas bp 498 of
the 2696r geneUL97was deleted (Fig. 3). This deletion results in a
codon frameshift and the introduction of a stop codon at bp 502 to
504 (corresponding to bp 503 to 505 of wild-type HCMV UL97).
The protein product of this mutated gene would be considerably
truncated (167 amino acids versus 707 amino acids for wild-type
[Towne strain] pUL97), lacking both an ATP binding site and a
substrate pocket (10, 35, 36). To confirm that pUL97 is truncated
in 2696r compared to pUL97 in the wild-type virus, Western blot
analysis was performed (Fig. 4). The results depict a significantly
lower molecular mass reactive species (molecular mass, 17.8 kDa)
in the 2696r lane that is absent from the wild-type lane. In addi-
tion, the reactive species corresponding to pUL97 in the wild-type
lane (molecular mass, 78.3 kDa) is absent from the 2696r lane.
These results demonstrate that pUL97 is indeed truncated in
2696r.
Recombinant HCMV UL97$498 exhibits resistance to both
CPV andGCV.To confirm that the bp 498 deletion of 2696r is the
mechanism by which this virus resists the antiviral effects of CPV,
this mutation was engineered into a wild-type virus (producing
HCMV UL97'498). Since previous studies have demonstrated
that UL97-null mutants have a 1- to 2-log growth defect that is
attributable to the loss of kinase activity (29, 37), and thus the
mutation discovered in 2696r would result in a virus without an
active pUL97 kinase, both 2696r and HCMV UL97'498 were as-
sayed for replication competency, and their growthwas compared
to the growth of awild-type virus. As shown in Fig. 5, in agreement
with previous results, 2696r (1.0$ 105& 0.17$ 105 PFU/ml) and
HCMV UL97'498 (1.5 $ 105 & 0.11 $ 105 PFU/ml) exhibited
growth defects in excess of 1 log unit compared to wild-type
(BAC-derived AD169rv) virus (2.8 $ 106 & 0.17 $ 106
PFU/ml).
Following confirmation that the engineered virus replicated
(albeit at a lower rate than that of the wild-type virus), cells in-
fected with HCMV UL97'498 were exposed to increasing con-
centrations of either CPV or GCV and were compared to wild-
type virus under the same conditions. The results, shown in Fig. 6
and Table 1, demonstrate that HCMV UL97'498 was approxi-
mately 72-fold more resistant to CPV (EC50 ! 25.8 & 3.1 "M)
and 14-fold more resistant to GCV (EC50! 28.1& 6.6 "M) than
the wild-type virus (BAC-derived AD169rv) (EC50s! 0.36& 0.11
and 2.0& 0.24"M, respectively).We conclude, therefore, that the
base pair deletion mutation in the open reading frame of the
HCMV gene UL97 is sufficient for drug resistance and that
the protein product of this gene is involved in the mechanism of
action of CPV.
FIG 2 Initial characterization of a CPV-resistant HCMV isolate (2696r). HFF
infected with the CPV-resistant HCMV isolate (dashed lines) were exposed to
increasing concentrations of either CPV (!) or GCV (Œ) and were compared
to HFF infected with wild-type virus (solid lines) exposed to the same concen-
trations of drugs. Values are means & standard deviations from at least two
experiments. Asterisks indicate that the replication of 2696r is significantly
different (P( 0.01) from that of the wild-type virus (with both drugs).
TABLE 1 Inhibition of 2696r and HCMV UL97'498 replication by ganciclovir and cyclopropavir
Compound












GCV 1.5& 0.16 41.3& 2.8 28 2.0& 0.24 28.1& 6.6 14
CPV 0.91& 0.15 22.5& 3.5 25 0.36& 0.11 25.8& 3.1 72
a Values are means& standard deviations from at least two experiments.
b Values are means& standard deviations from at least four experiments.
FIG 3 DNA sequencing of a CPV-resistant HCMV isolate (2696r). The ge-
nome of 2696r was isolated and sequenced using an ABI Prism 310 genetic
analyzer. The results are shown as a comparison of the wild-type and mutant
DNA sequences, with corresponding codon translation.
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CPV is a known inhibitor of HCMV replication (23). The hypoth-
esized mechanism by which CPV elicits this effect involves the
phosphorylation of CPV to amonophosphate by the viral enzyme
pUL97.Our current results demonstrate that a previously unchar-
acterized mutation in the open reading frame of UL97, which
would result in the expression of a truncated pUL97 lacking an
active kinase domain, renders the virus resistant to both CPV and
GCV. These results establish that pUL97 is necessary for CPV to
elicit an antiviral effect and, taken together with our previous re-
sults (24), establish that pUL97 is the enzyme responsible for the
initial phosphorylation of CPV to a monophosphate.
Previous studies have identified mutations within the HCMV
genome that confer resistance to CPV on the virus. The first ex-
ample is a frameshift mutation in UL27, developed as a result of
exposure to CPV, in a virus with wild-typeUL97 (38). This muta-
tion, presumably, compensates for the loss of pUL97 enzymatic
activity, since CPV exhibits some pUL97-inhibitory activity, and a
mutation responsible for HCMV resistance tomaribavir, a potent
pUL97 inhibitor, occurs in UL27 (38–40). Next, a recombinant
virus lacking a functional pUL97 kinase is 21-fold more resistant
to CPV than wild-type virus (23). The previously uncharacterized
mutation that we present in this study, which causes a frameshift
with a concomitant premature translational termination of the
viral kinase pUL97 and, presumably, a complete loss of enzymatic
function, behaves similarly to the previously characterized UL97-
nullmutantwith regard to growth characteristics (Fig. 5) andCPV
resistance (Fig. 6). Finally, somemutations generated as a result of
exposure to CPV confer resistance to the drug without the com-
plete loss of enzymatic function (41–43). These mutations confer
resistance not only to CPV but to GCV as well. The mutation
described here (UL97'498) also confers cross-resistance with
GCV, since GCV requires initial phosphorylation by pUL97 as
part of its mechanism of action (9).
Although there are many mutations that confer cross-resis-
tance between GCV and CPV, including the mutation we present
above, several mutations confer resistance to GCV but not to CPV
(41, 44, 45). This suggests that these two drugs either interact
differently or occupy different, though close, sites within the sub-
strate binding pocket of the pUL97 kinase. We therefore cannot
rule out the possibility that certain mutations inUL97may confer
resistance to CPV without conferring resistance to GCV. In addi-
tion, mutations that confer resistance to maribavir (46), a potent
pUL97 inhibitor (47), onHCMVdemonstrate no cross-resistance
with GCV (48). This suggests that these two nucleoside analogs
either interact differently or occupy distinct sites within the sub-
strate binding pocket of pUL97. Given that CPV demonstrates
characteristics of both GCV (substrate of pUL97 [24]) and
maribavir (inhibitor of pUL97 [38]), we hypothesize that CPV
binds to a site central to these two nucleoside analogs, occupying
space that would otherwise be occupied by either GCV ormariba-
vir. We further speculate that, given the possibility that CPV and
FIG 4 Western blot analysis of 2696r and wild-type (wt) HCMV pUL97. HFF
infected with 2696r or the wild type were harvested 4 days postinfection (MOI,
#1). Proteins from the cells were extracted and were analyzed via Western
blotting using an anti-pUL97 antibody. The locations of pUL97 from the wild-
type virus and of truncated pUL97 from 2696r are indicated. An anti-actin
antibody was used as a loading control. The positions of molecular weight
markers (in thousands) are indicated on the left.
FIG 5 Replication competency of HCMVUL97'498. HFF were infected with
a virus (wild-type AD169rv ["], HCMV UL97'498 [!], or 2696r [Œ]) at an
MOI of 0.02. Samples were taken every 24 h for 10 days; titers were determined
by plaque assays following serial dilution of samples. Values are means &
standard deviations from at least three experiments.
FIG 6 Resistance of HCMV UL97'498 to CPV and GCV. HFF infected with
awild-typeHCMVengineeredwith the deletion ofUL97 bp 498 (dashed lines)
were exposed to increasing concentrations of either CPV (!) or GCV (Œ) and
were compared to cells infected with a wild-type virus (solid lines) exposed to
the same concentrations of drugs. Values are means & standard deviations
from at least four experiments. Asterisks indicate that the replication of
HCMV UL97'498 is significantly different (P( 0.01) from that of the wild-
type virus (with both drugs).
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maribavir occupy similar sites within the substrate binding pocket
of pUL97, there could be mutations that confer resistance to both
CPV and maribavir. Given that maribavir and CPV are currently
being evaluated as candidates for clinical trials, an examination of
mutations that could confer cross-resistance to these nucleoside
analogs is warranted.
The use of CPV for the treatment or prophylaxis of HCMV
disease is promising. Our current results demonstrate that pUL97
is an integral part of themechanism of action of CPV. As such, it is
possible that cross-resistance between CPV and currently ap-
proved chemotherapeutics for the treatment of HCMV may oc-
cur. However, this has not been observed in clinic. In fact, clinical
strains ofHCMV resistant toGCVwere sensitive to earlier analogs
of CPV (49). Also, the increased antiviral activitywith no observed
increase in toxicity (22) and the ability to achieve therapeutic con-
centrations in vivo without prodrug modification (5, 20) are two
reasons why CPV should be superior to GCV for the treatment of
HCMV disease. Further examination of the mechanism of action
and preclinical development of this compound is warranted.
ACKNOWLEDGMENTS
This work was supported by grants from the NIH (CA32779, AI26077,
GM103433-10), Microbiotix, Inc., and the American Heart Association
(12GRNT11890012), as well as by funds from the University of Michigan
and Drake University.
REFERENCES
1. Ho M. 2008. The history of cytomegalovirus and its diseases. Med. Mi-
crobiol. Immunol. 197:65–73.
2. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. 2013.
The “silent” global burden of congenital cytomegalovirus. Clin. Micro-
biol. Rev. 26:86–102.
3. Andrei G, De Clercq E, Snoeck R. 2009. Drug targets in cytomegalovirus
infection. Infect. Disord. Drug Targets 9:201–222.
4. Biron KK. 2006. Antiviral drugs for cytomegalovirus diseases. Antiviral
Res. 71:154–163.
5. Cocohoba JM, McNickoll IR. 2002. Valganciclovir: an advance in cyto-
megalovirus therapeutics. Ann. Pharmacother. 36:1075–1079.
6. Faulds D, Heel RC. 1990. Ganciclovir: a review of its antiviral activity,
pharmacokinetic properties, and therapeutic efficacy in cytomegalovirus
infections. Drugs 39:597–638.
7. Noble S, Faulds D. 1998. Ganciclovir: an update of its use in the preven-
tion of cytomegalovirus infection and disease in transplant recipients.
Drugs 56:115–146.
8. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA,
Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector
SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA,
Kessler HA. 1998. Guidelines for the treatment of cytomegalovirus dis-
eases in patients with AIDS in the era of potent antiretroviral therapy:
recommendations of an international panel. International AIDS Soci-
ety—USA. Arch. Intern. Med. 158:957–969.
9. Littler E, Stuart AD, Chee MS. 1992. Human cytomegalovirus UL97
open reading frame encodes a protein that phosphorylates the antiviral
nucleoside analogue ganciclovir. Nature 358:160–162.
10. He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM. 1997.
The human cytomegalovirus UL97 protein is a protein kinase that auto-
phosphorylates on serines and threonines. J. Virol. 71:405–411.
11. Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, Nelson
DJ. 1985. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts in-
fected with human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 82:
2473–2477.
12. Boehme RE. 1984. Phosphorylation of the antiviral precursor 9-(1,3-
dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate ki-
nase isozymes. J. Biol. Chem. 259:12346–12349.
13. Freitas VR, Smee DF, Chernow M, Boehme R, Matthews TR. 1985.
Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with
that of acyclovir against human, monkey, and rodent cytomegaloviruses.
Antimicrob. Agents Chemother. 28:240–245.
14. Matthews T, Boehme R. 1988. Antiviral activity andmechanism of action
of ganciclovir. Rev. Infect. Dis. 10:S490–S494.
15. Hamzeh FM, Lietman PS, Gibson W, Hayward GS. 1990. Identification
of the lytic origin of DNA replication in human cytomegalovirus by a
novel approach utilizing ganciclovir-induced chain termination. J. Virol.
64:6184–6195.
16. Hamzeh FM, Lietman PS. 1991. Intranuclear accumulation of sub-
genomic noninfectious human cytomegalovirus DNA in infected cells in
the presence of ganciclovir. Antimicrob. Agents Chemother. 35:1818–
1823.
17. Baldanti F, Lurain N, Gerna G. 2004. Clinical and biologic aspects of
human cytomegalovirus resistance to antiviral drugs. Hum. Immunol.
65:403–409.
18. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses
to antiviral drugs: clinical impacts and molecular mechanisms. Drug
Resist. Updat. 5:88–114.
19. Gilbert C, Boivin G. 2005. Human cytomegalovirus resistance to antiviral
drugs. Antimicrob. Agents Chemother. 49:873–883.
20. Bowlin TL, Brooks JL, Zemlicka J. 2009. Preclinical pharmacokinetic,
toxicokinetic and toxicology results for cyclopropavir, a promising new
agent for the treatment of beta- and gamma-herpesviruses. Antiviral Res.
82:A46–A47.
21. Kern ER, Bidanset DJ, Harline CB, Yan Z, Zemlicka J, Quenelle DC.
2004. Oral activity of a methylenecyclopropane analog, cyclopropavir, in
animal models for cytomegalovirus infections. Antimicrob. Agents Che-
mother. 48:4745–4753.
22. Zhou S, Breitenbach JM, Borysko KZ, Drach JC, Kern ER, Gullen E,
Cheng YC, Zemlicka J. 2004. Synthesis and antiviral activity of (Z)- and
(E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and
-pyrimidines: second-generation methylenecyclopropane analogues of
nucleosides. J. Med. Chem. 47:566–575.
23. Kern ER, Kushner NL, Hartline CB, Williams-Aziz SL, Harden EA,
Zhou S, Zemlicka J, Prichard MN. 2005. In vitro activity and mechanism
of action of methylenecyclopropane analogs of nucleosides against her-
pesvirus replication. Antimicrob. Agents Chemother. 49:1039–1045.
24. Gentry BG, Kamil JP, Coen DM, Zemlicka J, Drach JC. 2010. Stereo-
selective phosphorylation of cyclopropavir by pUL97 and competitive in-
hibition by maribavir. Antimicrob. Agents Chemother. 54:3093–3098.
25. Gentry BG, Gentry SN, Jackson TL, Zemlicka J, Drach JC. 2011.
Phosphorylation of antiviral and endogenous nucleotides to di- and
triphosphates by guanosine monophosphate kinase. Biochem. Pharma-
col. 81:43–49.
26. Shipman C, Jr. 1969. Evaluation of 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid (HEPES) as a tissue culture buffer. Proc. Soc. Exp. Biol.Med.
130:305–310.
27. Hobom U, Brune W, Messerle M, Hahn G, Koszinowski UH. 2000. Fast
screening procedures for random transposon libraries of cloned herpesvi-
rus genomes: mutational analysis of human cytomegalovirus envelope
glycoprotein genes. J. Virol. 74:7720–7729.
28. Klein RJ. 1975. Isolation of herpes simplex virus clones and drug resistant
mutants in microcultures. Arch. Virol. 49:73–80.
29. Kamil JP, Coen DM. 2007. Human cytomegalovirus protein kinase UL97
forms a complex with the tegument phosphoprotein pp65. J. Virol. 81:
10659–10668.
30. Tischer BK, von Einem J, Kaufer B, Osterrieder N. 2006. Two-step
red-mediated recombination for versatile high-efficiencymarkerlessDNA
manipulation in Escherichia coli. Biotechniques 40:191–197.
31. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a
two step markerless red recombination system. Methods Mol. Biol. 634:
421–430.
32. Wang D, Li G, Schauflinger M, Nguyen CC, Hall ED, Yurochko AD,
von Einem J, Kamil JP. 2013. The ULb= region of the human cytomega-
lovirus genome confers an increased requirement for the viral protein
kinase UL97. J. Virol. 87:6359–6376.
33. Kalejta RF, Bechtel JT, Shenk T. 2003. Human cytomegalovirus pp71
stimulates cell cycle progression by inducing the proteasome-dependent
degradation of the retinoblastoma family of tumor suppressors.Mol. Cell.
Biol. 23:1885–1895.
34. Jarosinski KW, Hunt HD, Osterrieder N. 2010. Down-regulation of
MHC class I by the Marek’s disease virus (MDV) UL49.5 gene product
Resistance of HCMV to Cyclopropavir Maps to UL97
September 2013 Volume 57 Number 9 aac.asm.org 4347
 on Septem






mildly affects virulence in a haplotype-specific fashion. Virology. 405:
457–463.
35. Michel D, Pavic I, Zimmermann A, Haupt E, Wunderlich K, Heu-
schmid M, Mertens T. 1996. The UL97 gene product of human cytomeg-
alovirus is an early-late protein with a nuclear localization but is not a
nucleoside kinase. J. Virol. 70:6340–6346.
36. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK.
1992. A protein kinase homologue controls phosphorylation of ganciclo-
vir in human cytomegalovirus-infected cells. Nature 358:162–164.
37. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM,
Parker BO, Pari GS. 1999. A recombinant human cytomegalovirus with
a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:
5663–5670.
38. James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engeltha-
ler DM, Keim PS, Bowlin TL, Kern ER, Prichard MN. 2011. Cyclo-
propavir inhibits the normal function of the human cytomegalovirus
UL97 kinase. Antimicrob. Agents Chemother. 55:4682–4691.
39. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC. 2003.
Resistance of human cytomegalovirus to the benzimidazole L-ribonucle-
oside maribavir maps to UL27. J. Virol. 77:11499–11506.
40. Prichard MN. 2009. Function of human cytomegalovirus UL97 kinase in
viral infection and its inhibition by maribavir. Rev. Med. Virol. 19:215–
229.
41. Chou S, Bowlin TL. 2011. Cytomegalovirus UL97 mutations affecting
cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Che-
mother. 55:382–384.
42. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van Den Bogaard
M, Stamminger T. 2001. Inhibitors of human cytomegalovirus replica-
tion drastically reduce the activity of the viral protein kinase pUL97. J.
Gen. Virol. 82(Part 6):1439–1450.
43. Michel D, Schaarschmidt P, Wunderlich K, Heuschmid M, Simoncini
L, Muhlberger D, Zimmermann A, Pavic I, Mertens T. 1998. Functional
regions of the human cytomegalovirus protein pUL97 involved in nuclear
localization and phosphorylation of ganciclovir and pUL97 itself. J. Gen.
Virol. 79(Part 9):2105–2112.
44. Chou S, Marousek G, Bowlin TL. 2012. Cyclopropavir susceptibility of
cytomegalovirus DNA polymerase mutants selected after antiviral drug
exposure. Antimicrob. Agents Chemother. 56:197–201.
45. Erice A. 1999. Resistance of human cytomegalovirus to antiviral drugs.
Clin. Microbiol. Rev. 12:286–297.
46. Chou S, Wechel LC, Marousek GI. 2007. Cytomegalovirus UL97 kinase
mutations that confer maribavir resistance. J. Infect. Dis. 196:91–94.
47. Evers DL, Komazin G, Ptak RG, Shin D, Emmer BT, Townsend LB,
Drach JC. 2004. Inhibition of human cytomegalovirus replication by
benzimidazole nucleosides involves three distinct mechanisms. Antimi-
crob. Agents Chemother. 48:3918–3927.
48. Chou S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir
and maribavir. Rev. Med. Virol. 18:233–246.
49. Baldanti F, Sarasini A, Drach JC, Zemlicka J, Gerna G. 2002. Z-isomers
of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and
guanine (synguanol) are active against ganciclovir- and foscarnet-
resistant human cytomegalovirus UL97 mutants. Antiviral Res. 56:273–
278.
Gentry et al.
4348 aac.asm.org Antimicrobial Agents and Chemotherapy
 on Septem
ber 15, 2013 by W
AYNE STATE UNIVERSITY
http://aac.asm
.org/
Downloaded from
 
